Nandanwar Manohar, Sharma Vijay, Karade Avinash, Sharma Anuka, Kansagara Atul, Sakhalkar Ulka, Sidhu Yasmeen, Gupta Sangita, Patel Muftedar, Ghorpade Parag
Wockhardt Research Centre, D-4, MIDC, Chikalthana, Aurangabad, 431 006 Maharashtra India.
Wockhardt Hospitals Ltd, Dr. Anand Rao Nair Marg, Mumbai, 400 011 Maharashtra India.
J Diabetes Metab Disord. 2021 Sep 27;20(2):1583-1595. doi: 10.1007/s40200-021-00906-z. eCollection 2021 Dec.
The investigation of wound healing potential of human GFC (growth factor concentrate) was undertaken in diabetic and non-diabetic rats. Primarily, GFC is the combination of several growth factors present in blood which has potential of wound healing. In present study, WCK-GFC kit, a single step optimized kit was used for obtaining human GFC.
Diabetes in rats was induced by intraperitoneal single injection of 40 mg/kg streptozotocin (STZ). The full thickness circular wounds of 2 cm area were created using sterilized stainless steel biopsy punch. Non-diabetic wounds were topically treated with 100µL and 300µL of GFC, while diabetic wounds were treated with 300µL of GFC. The standard of care treatment groups were included, wherein the non-diabetic and diabetic wound were topically treated with Nadoxin and Z-AD-G skin cream, respectively. The percentage of wound contraction was measured on weekly intervals. At the end of study duration, tissues from wound were collected for histopathological evaluation.
Both diabetic and non-diabetic GFC treated rats exhibited a significantly higher rate of wound contraction on day 8 and 15 compared to normal untreated control group and standard-of-care treated rats. Wound healing was induced by GFC through rapid re-epithelialization. On comparing wound healing with standard-of care agent, the GFC treated wounds demonstrated a faster remodeling phase, a better organization and lower inflammation.
The current study demonstrates that topically applied GFC promotes healing of wounds, with enhanced wound contraction in both non-diabetic and diabetic rats.
在糖尿病大鼠和非糖尿病大鼠中对人生长因子浓缩物（GFC）的伤口愈合潜力进行了研究。首先，GFC是血液中几种具有伤口愈合潜力的生长因子的组合。在本研究中，使用了一种单步优化试剂盒WCK - GFC来获取人GFC。
通过腹腔单次注射40mg/kg链脲佐菌素（STZ）诱导大鼠患糖尿病。使用消毒的不锈钢活检打孔器制作面积为2平方厘米的全层圆形伤口。非糖尿病伤口分别用100μL和300μL的GFC进行局部治疗，而糖尿病伤口用300μL的GFC进行治疗。纳入了标准护理治疗组，其中非糖尿病和糖尿病伤口分别用Nadoxin和Z - AD - G皮肤乳膏进行局部治疗。每周测量伤口收缩百分比。在研究结束时，收集伤口组织进行组织病理学评估。
与未治疗的正常对照组和标准护理治疗的大鼠相比，糖尿病和非糖尿病GFC治疗的大鼠在第8天和第15天均表现出显著更高的伤口收缩率。GFC通过快速重新上皮化诱导伤口愈合。与标准护理药物比较伤口愈合情况时，GFC治疗的伤口显示出更快的重塑阶段、更好的组织结构和更低的炎症。
当前研究表明，局部应用GFC可促进伤口愈合，在非糖尿病和糖尿病大鼠中均增强了伤口收缩。
